Skip to main content

Tweets

Nuclear imaging assesses cardiac function, anatomy & microvascular dysfunction (MD). MD is underrecognized but can be measured by coronary flow reserve. MD is associated with worse longterm outcomes in systemic inflammatory disease – Dr. Weber #RNL2024 @rheumnow https://t.co/Bv22UKi6mM
TheDaoIndex @KDAO2011 ( View Tweet )
2 years ago
Coronary Microvascular Dysfunction is associated with poor prognosis/outcomes in our systemic inflammatory disease patients. What is the gold standard for evaluating microvascular dysfunction? Coronary Flow Reserve (CRF) This is only one component to fully understand and assess… https://t.co/bMV5npkFwm https://t.co/ZYBXpQLPIF
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years ago
Link between inflammation and cardiovascular disease, increased 1.5x in RA and 2-3 in PsA, treating inflammation is important to reduce CV risk, Brittany Weber #RNL2024 @RheumNow https://t.co/FCrOxa3drZ
Dr. Antoni Chan @synovialjoints ( View Tweet )
2 years ago
Dr. B Weber gave a wonderful review of inflammation and cardiac risk in SLE, PsO/PsA, and RA. *SLE pts has a 50-fold increased risk of MI *RA pts are a 1.5x risk of CVD *PsO and PsA pts are also at increased risk for CVD #RNL2024 @RheumNow https://t.co/Hy4TmLzhzO
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years ago
"The link between RA and CVD is the shared inflammatory pathways involving IL-1, IL-6 and TNF" -Dr. B Weber #RNL2024 @rheumnow https://t.co/aGPA8ZFNHj
TheDaoIndex @KDAO2011 ( View Tweet )
2 years ago
CV disease risk is increased in patients with inflammatory rheumatic diseases. More data emerging in SLE, psoriasis, RA. – Dr. B Weber #RNL2024 @rheumnow https://t.co/wF9izGZug3
TheDaoIndex @KDAO2011 ( View Tweet )
2 years ago
#RNL2024 @RheumNow Weber: Asymptomatic Lupus has higher rate of atherosclerosis at all age grps 35-44 yo F with SLE: 50X increased risk of MI compared to healthy pts in Framingham RA pts at 1.5x risk of CVD https://t.co/TJ5dLXwvNc
Eric Dein @ericdeinmd ( View Tweet )
2 years ago
#RNL2024 @RheumNow Brittany Weber on Cardio-Rheumatology: "Everything has changed" on inflammation and CVD - Canakinumab 150 mg v PBO HR 0.85, p =0.02 - Colchicine v PBO HR 0.69, P<0.001 2023: FDA approval for colchicine as 1st anti-inflammatory for reducing CV events https://t.co/Tlv5Np2BHf
Eric Dein @ericdeinmd ( View Tweet )
2 years ago
Check out some of the "newer" modalities available to us for evaluation of our rheumatology patients to better understand their cardiac risk. "Everything has changed in cardiac rheumatology." Dr. B. Weber #RNL2024 @RheumNow https://t.co/fki73W4Fk8
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years ago
Dr. B Weber discusses new CV Imaging Tools beyond the exercise EKG and ECHO to assess our rheum patients who are at higher risk for CV disease: coronary CT, Stress CMR, stress PET #RNL2024 @RheumNow https://t.co/DAuUptHMuF
TheDaoIndex @KDAO2011 ( View Tweet )
2 years ago
Dr. Brittany Weber showcases the diverse manifestations that we can see in rheumatology and the increasing complexity and use of imaging in field. #RNL2024 @RheumNow https://t.co/0dOJdPazXL
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years ago
Ready to get your #GameOn at #RNL2024 @RheumNow https://t.co/joP1xcU0TH
Dr. Rachel Tate @uptoTate ( View Tweet )
2 years ago
×